Skip to main content

Table 2 Diagnostic performance of different CSF analytes with 18F-flutemetamol PET as autopsy-validated standard of truth (EUROIMMUN assay)

From: Diagnostic value of cerebrospinal fluid Aβ ratios in preclinical Alzheimer’s disease

  AUC SE 95 % CI Cutoffa Sensitivity (%) Specificity (%) Correctly classifiedb (%)
Aβ38 0.571 0.111 0.401–0.730 2909 100 32.26 45
Aβ40 0.571 0.112 0.401–0.730 10738 100 29.03 42
Aβ42*† 0.908 0.051 0.769–0.977 745 100 74.19 79
ttau 0.724 0.148 0.555–0.856 436 71.43 80.65 76
Aβ42/Aβ38* 0.935 0.039 0.806–0.989 0.332 100 87.10 89
Aβ42/Aβ40*† 0.954 0.033 0.832–0.995 0.096 100 80.65 84
Aβ42/ttau*† 0.963 0.028 0.846–0.998 2.006 100 87.10 89
  1. Analyte concentrations are described as pg/ml or calculated as ratios between concentrations of two analytes
  2. Statistically significant differences of AUCs between analytes: *P corrected < 0.05 compared with Aβ40; †P corrected < 0.05 compared with Aβ38. No other differences of AUCs were found
  3. aCutoff value corresponding to the highest Youden index
  4. bPercentage of positively classified cases based on the CSF cutoff compared with amyloid PET classification
  5. amyloid beta, AUC area under the receiver operating characteristic curve, CI confidence interval, CSF cerebrospinal fluid, PET positron emission tomography, SE standard error, ttau total tau